PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.07%
Revenue growth under 50% of MRVL's 15.46%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-6.06%
Negative gross profit growth while MRVL is at 12.72%. Joel Greenblatt would examine cost competitiveness or demand decline.
-10.44%
Negative EBIT growth while MRVL is at 83.91%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-10.44%
Negative operating income growth while MRVL is at 83.91%. Joel Greenblatt would press for urgent turnaround measures.
-4.25%
Negative net income growth while MRVL stands at 88.60%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-4.44%
Negative EPS growth while MRVL is at 88.66%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2.27%
Negative diluted EPS growth while MRVL is at 88.66%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.21%
Share reduction while MRVL is at 0.55%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.72%
Reduced diluted shares while MRVL is at 0.55%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.46%
Dividend growth of 0.46% while MRVL is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
102.70%
OCF growth at 50-75% of MRVL's 137.99%. Martin Whitman would question if the firm lags in monetizing sales effectively.
243.37%
FCF growth above 1.5x MRVL's 105.64%. David Dodd would verify if the firm’s strategic investments yield superior returns.
91.91%
10Y revenue/share CAGR under 50% of MRVL's 1028.90%. Michael Burry would suspect a lasting competitive disadvantage.
76.29%
5Y revenue/share CAGR under 50% of MRVL's 351.59%. Michael Burry would suspect a significant competitive gap or product weakness.
17.50%
3Y revenue/share CAGR under 50% of MRVL's 119.11%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
123.71%
10Y OCF/share CAGR at 50-75% of MRVL's 245.58%. Martin Whitman might fear a structural deficiency in operational efficiency.
171.96%
5Y OCF/share CAGR above 1.5x MRVL's 67.17%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-13.46%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
311.00%
Positive 10Y CAGR while MRVL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
66.06%
5Y net income/share CAGR above 1.5x MRVL's 32.15%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
11.12%
Positive short-term CAGR while MRVL is negative. John Neff would see a clear advantage in near-term profit trajectory.
100.48%
Below 50% of MRVL's 1184.87%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
16.45%
Below 50% of MRVL's 36.15%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
5.88%
Below 50% of MRVL's 26.86%. Michael Burry suspects a serious short-term disadvantage in building book value.
361.29%
Dividend/share CAGR of 361.29% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
366.79%
Dividend/share CAGR of 366.79% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
652488.96%
3Y dividend/share CAGR of 652488.96% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-2.04%
Firm’s AR is declining while MRVL shows 2.72%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-4.60%
Inventory is declining while MRVL stands at 29.20%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
0.68%
Asset growth well under 50% of MRVL's 2.02%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
2.34%
1.25-1.5x MRVL's 1.89%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
3.89%
R&D growth drastically higher vs. MRVL's 6.78%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-8.88%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.